DUSSELDORF, Germany – Celebrating breakthrough innovation in AI-driven cancer diagnostics, DoMore Diagnostics was named the winner of the European 42PLUS1 Pitch Competition 2024 .
The company’s cutting-edge technology leverages artificial intelligence to make personalized treatment decisions simple, scalable, and accessible for cancer patients worldwide.
Following their victory and recent funding milestones, we sat down with Torbjørn Furuseth, MD , CEO and Co-Founder of DoMore Diagnostics, to discuss their journey, their rigorous due diligence experience, and the future of digital biomarkers.
Making Personalized Treatment Simple and Accessible Interviewer: Thank you for joining us today, Torbjørn.
